Sol-Gel Technologies Free Cash Flow 2016-2023 | SLGL
Sol-Gel Technologies free cash flow from 2016 to 2023. Free cash flow can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures.
| Sol-Gel Technologies Annual Free Cash Flow |
| 2023 |
-17.79 |
| 2022 |
-9.66 |
| 2021 |
-7.83 |
| 2020 |
-25.69 |
| 2019 |
-23.10 |
| 2018 |
-24.52 |
| 2017 |
-26.01 |
| 2016 |
-18.88 |
| 2015 |
-8.34 |
| Sol-Gel Technologies Quarterly Free Cash Flow |
| 2023-12-31 |
-17.79 |
| 2023-09-30 |
|
| 2023-06-30 |
-8.43 |
| 2023-03-31 |
|
| 2022-12-31 |
-9.66 |
| 2022-09-30 |
|
| 2022-06-30 |
-6.65 |
| 2022-03-31 |
|
| 2021-12-31 |
-7.83 |
| 2021-09-30 |
|
| 2021-06-30 |
-11.42 |
| 2021-03-31 |
|
| 2020-12-31 |
-25.69 |
| 2020-09-30 |
|
| 2020-06-30 |
-9.94 |
| 2020-03-31 |
|
| 2019-12-31 |
-23.10 |
| 2019-09-30 |
|
| 2019-06-30 |
-13.11 |
| 2019-03-31 |
|
| 2018-06-30 |
-8.88 |
| 2018-03-31 |
|
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2016-12-31 |
|
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.026B |
$0.002B |
|
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
|
